Surgery
Cytoreductive Surgery With or Without HITHOC for Pleural Mesothelioma: A Meta-analysis of Survival and Perioperative Outcomes
Annals of Surgical Oncology 2026 March 16 [Link] Lucas Monteiro Delgado, Rachid Eduardo Noleto da Nobrega Oliveira, Guilherme Franceschini Machado, Luiza Soares Guerra, Cauã de Toledo Corrêa, Mario Claudio Ghefter, Paulo Manuel-Pêgo Fernandes, Marcello Migliore, Ricardo Mingarini Terra, Paula Duarte D’Ambrosio Abstract Background: Pleural mesothelioma (PM) is a rare and aggressive malignancy with limited overall…
Read MorePivotal role of long non-coding RNA in the development of new therapeutic approaches for pleural mesothelioma
Discover Oncology 2026 March 12 [Link] Caroline Joseph Kiriacos, Dina M Elkahwagy, Manar Mansour Abstract Pleural mesothelioma is a rare aggressive tumor that affects the parietal layer of the pleura. It constitutes 90% of mesotheliomas. Usually, the diagnosis takes place 30 to 40 years after asbestos exposure. Thus, patients are diagnosed at a very late…
Read MoreHormonal Status May Contribute to Sex-Based Survival Differences in Epithelioid Peritoneal Mesothelioma
Annals of Surgical Oncology 2026 March 12 [Link] Kaelyn C Cummins, Olivia Sears, Elio R Bitar, Chengli Shen, Allan Tsung, Samantha M Ruff Abstract Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is central to treating patients with epithelioid peritoneal mesothelioma (EPM). Male sex is a negative prognostic factor in mesothelioma, but the reasons…
Read MoreAdvancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment
AAPS PharmSciTech 2026 March 4 [Link] Mural Quadros, Naveen Rajana, Vivek Gupta Abstract Despite advances in mesothelioma treatment, malignant pleural mesothelioma (MPM) continues to present a poor prognosis due to its aggressive progression and resistance to conventional therapies. Current treatment modalities, including surgery, chemotherapy, radiation, and immunotherapy, offer limited efficacy, with a five-year survival rate…
Read MorePresent and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review
European Respiratory Review 2026 February 18 [Link] Amro Hajja, Miral Atout, Rasoul Turko, Haadi Syed, Paula Duarte D’Ambrosio, Ricardo Mingarini Terra, Amal Abdulhaq, Marco Nardini, Marcello Carlo Ambrogi, Marco Lucchi, Hassan Robaidi, Waleed Saleh, Khaled AlKattan, Marcello Migliore Abstract Background: Pleural malignancies pose a significant clinical challenge due to their poor prognosis and limited treatment…
Read MoreThe Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma
Cancers 2026 January 27 [Link] Luca Dominici, Davide Franceschini, Mauro Loi, Ruggero Spoto, Antonio Marco Marzo, Beatrice Marini, Mariya Boyanova Ilieva, Nicola Lambri, Francesco La Fauci, Ciro Franzese, Marta Scorsetti Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm, the major cause of which is asbestos exposure. Adjuvant radiotherapy after pleurectomy/decortication (P/D) aims at…
Read MoreThe Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma
Cancers 2026 January 27 [Link] Luca Dominici, Davide Franceschini, Mauro Loi, Ruggero Spoto, Antonio Marco Marzo, Beatrice Marini, Mariya Boyanova Ilieva, Nicola Lambri, Francesco La Fauci, Ciro Franzese, Marta Scorsetti Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm, the major cause of which is asbestos exposure. Adjuvant radiotherapy after pleurectomy/decortication (P/D) aims at…
Read MoreFeasibility of multimodality treatment, including pleurectomy decortication, in carefully selected patients with sarcomatoid mesothelioma
Translational Lung Cancer Research 202t6 January 31 [Link] Moshe Lapidot, Emanuele Mazzola, Raphael Bueno Abstract Background: Pleural mesothelioma (PM) represents an uncommon and exceptionally lethal malignancy. The sarcomatoid subtype constitutes the rarest histological variant, traditionally linked to the worst prognosis, while the advantages of operative intervention remain inadequately established. In this study, we present findings…
Read MoreDisaster on MARS2? Lessons Learned from Modern Day Outcomes of Surgery for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 February 2 [Link] Shubham Gulati, Andrea Wolf, Jai Mehrotra-Varma, Stephanie Tuminello, Emanuela Taioli, Raja Flores Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS2) trial has drawn into question pleurectomy/decortication (PD) for the treatment of pleural mesothelioma. This trial’s evaluation of resectability (poor positron emission tomography/computed tomography utilization, patients…
Read MoreNeoadjuvant Pressurized Intraperitoneal Aerosol Chemotherapy for Conversion to Cytoreductive Surgery in Unresectable Malignant Peritoneal Mesothelioma: A Report of 2 Cases
The American Journal of Case Reports 2026 February [Link] Arnaldo Urbano-Ruiz, Bruna Latronico Palma, Ronaldo Elias Carnut Rego, Daniel Bianqui Guaraldo da Silva, Bianca Fava, Erlan Araujo Falcão , Michelle Louise Rodrigues Barbosa da Silva, Julia Rodrigues Leandro Uliano Abstract BACKGROUND Peritoneal mesothelioma (PM) is the second most common presentation site of malignant mesothelioma. The…
Read More
Skip to content